Activity of quinolones against gram-positive cocci: Mechanisms of drug action and bacterial resistance

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 21, Issue 9, 2002, Pages 647-659

  Schmitz, F J ^a   Higgins, P ^a   Mayer, S ^a   Fluit, A ^b   Dalhoff, A ^c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AM 1147; BMS 294756; CIPROFLOXACIN; CLINAFLOXACIN; COAGULASE; COUMARIN DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; DU 6959; DV 7751 A; ENOXACIN; FLEROXACIN; GARENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PAZUFLOXACIN; PGE 4175997; PGE 9262932; PGE 9509924; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; TOSUFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL; BACTERIAL MUTATION; CELL LEVEL; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TRANSPORT; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE MUTATION; GRAM POSITIVE COCCI; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; PUMP; REVIEW; SPECIES; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; FLUOROQUINOLONES; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0036387387     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-002-0788-z     Document Type: Review

References (136)

1. Smith JT (1986) The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 18:21-29
2. Roca J (1995) The mechanisms of DNA topoisomerases. Trends Biochem Sci 20:156-160
3. Gellert M, Mizuuchi K, O'Dea MH, Nash HA (1976) DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 73:3872-3876
4. Drlica K, Zhao XL (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61:377-392
5. Kampranis SC, Maxwell A (1996) Conversion of DNA gyrase into a conventional type II topoisomerase. Proc Natl Acad Sci USA 93:14416-14421
6. Critchlow SE, Maxwell A (1996) DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase - DNA complex. Biochemistry 35:7387-7393
7. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379:225-232
8. Gellert M, O'Dea MH, Mizuuchi M, Itoh T, Tomizawa JL (1977) Nalidixic acid: a second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci USA 74:4772-4776
9. Higgins CF, Dorman CJ, Stirling DA, Wadell L, Booth IR (1988) A physiological role for DNA supercoiling in the osmotic regulation of gene expression of Salmonella typhimurium and Escherichia coli. Cell 52:569-584
10. Hsieh LS, Burger RM, Drlica K (1991) Bacterial DNA supercoiling and [ATP]/[ADP]: changes associated with a transition to anaerobic growth. J Mol Biol 219:443-450
11. Hsieh LS, Rouviere-Yaniv J, Drlica K (1991) Bacterial DNA supercoiling and [ATP]/[ADP]: changes associated with salt shock. J Bacteriol 173:3914-3917
12. Friedman SM, Malik M, Drlica K (1995) DNA supercoiling in a thermotolerant mutant of Escherichia coli. Mol Gen Genet 248:417-422
13. Goldstein E, Drlica K (1984) Regulation of bacterial DNA supercoiling: plasmid linking number varies with growth temperature. Proc Natl Acad Sci USA 81:4046-4050
14. Mizushima T, Natori S, Sekimizu K (1993) Relaxation of supercoiled DNA associated with induction of heat shock proteins in Escherichia coli. Mol Gen Genet 328:1-5
15. Karem K, Foster J (1993) The influence of DNA topology on the environment of a pH-regulated locus in Salmonella typhi-murium. Mol Microbiol 10:75-86
16. Steck TR, Pruss GJ, Manes SH, Burg L, Drlica K (1984) DNA supercoiling in gyrase mutants. J Bacteriol 158:397-403
17. Kreuzer KN, Cozzarelli NR (1979) Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription and bacteriophage growth. J Bacteriol 140:424-435
18. Di Nardo S, Voelkel K, Sternglanz R, Reynolds A, Wright A (1982) Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. Cell 31:43-51
19. Gellert M, Menzel R, Mizuuchi D, Nash H (1983) Regulation of DNA supercoiling in Escherichia coli. Cold Spring Harbor Symposia Quant Biol 47:763-767
20. Pruss GJ, Manes H, Drlica K (1982) Escherichia coli DNA topoisomerase I mutants: increased supercoiling is corrected by mutations near gyrase genes. Cell 31:35-42
21. Menzel R, Gellert M (1983) Regulation of the genes for Escherichia coli DNA gyrase: homeostatic control of DNA supercoiling. Cell 34:105-113
22. Zechiedrich EL, Cozzarelli N (1995) Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. Genes Dev 9:2859-2869
23. Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H (1990) New topoisomerase essential for chromosome segregation in E. coli. Cell 63:393-404
24. Peng H, Marians KJ (1995) The interaction of Escherichia coli topoisomerase IV with DNA. J Biol Chem 270:25286-25290
25. Zechiedrich EL, Khodursky A, Cozzarelli N (1997) Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli. Genes Dev 11:2580-2592
26. Khodursky AB, Zechiedrich EL, Cozzarelli NR (1995) Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 92:11801-11805
27. Peng H, Marians KJ (1993) Escherichia coli topoisomerase IV - purification, characterization, subunit structure, and subunit interactions. J Biol Chem 268:24481-24490
28. Snyder M, Drlica K (1979) DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J Mol Biol 131:287-302
29. Kampranis SC, Maxwell A (1998) The DNA gyrase-quinolone complex - ATP hydrolysis and the mechanism of DNA cleavage. J Biol Chem 273:22615-22626
30. Kampranis SC, Maxwell A (1998) Conformational changes in DNA gyrase revealed by limited proteolysis. J Biol Chem 273:22606-22614
31. Hiasa H, Yousefs D, Marians KJ (1996) DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone ternary complex. J Biol Chem 271:26424-26429
32. Marians KJ, Hiasa H (1997) Mechanism of quinolone action - a drug-induced structural perturbation of the DNA precedes strand cleavage by topoisomerase IV. J Biol Chem 272:9401-9409
33. Maxwell A (1997) DNA gyrase as a drug target. Trends Microbiol 5:102-109
34. Drlica K (1999) Mechanism of fluoroquinolone action. Curr Opin Microbiol 2:504-508
35. Anderson V, Gootz T, Osheroff N (1998) Topoisomerase IV catalysis and the mechanism of quinolone action. J Biol Chem 273:17879-17885
36. Chen CR, Malik M, Snyder M, Drlica K (1996) DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage. J Mol Biol 258:627-637
37. Khodursky AB, Cozzarelli N (1998) The mechanism of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 273:27668-27677
38. Crumplin GC, Smith JT (1975) Nalidixic acid: an antibacterial paradox. Antimicrob Agents Chemother 8:251-261
39. Deitz WH, Cook TM, Gloss WA (1966) Mechanism of action of nalidixic acid on Escherichia coli. Conditions required for lethality. J Bacteriol 91:768-773
40. Lewin C, Howard B, Smith JT (1991) Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase. J Med Microbiol 34:19-22
41. Philips I, Culebras E, Moreno F, Baquero F (1987) Induction of the SOS-response by new 4-quinolones. J Antimicrob Chemother 20:631-638
42. Heisig P (1996) Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 40:879-885
43. Shreedhan S, Oram M, Jensen B, Peterson LR, Fisher LM (1990) DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarities with quinolone resistance mutations in Escherichia coli. J Bacteriol 172:7260-7262
44. Pan XS, Ambler J, Mehtar S, Fisher LM (1996) Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 40:2321-2326
45. Ng EY, Trucksis M, Hooper DC (1996) Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 40:1881-1888
46. Munoz R, de la Campa AG (1996) ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 40:2252-2257
47. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L (1996) High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 40:2760-2764
48. Ferrero L, Cameron B, Crouzet J (1995) Analysis ofgyrA and grlA mutations in stepwise selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 39:1554-1558
49. Ito H, Yoshida H, Bogaki-Shonai M, Niga T, Hattori H, Nakamura S (1994) Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother 38:2014-2023
50. Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 34:1271-1272
51. Cabral JHM, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC (1997) Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 388:903-906
52. Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S (1991) Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother 35:1647-1650
53. Willmott CJR, Maxwell A (1993) A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob Agents Chemother 37:126-127
54. Heddle J, Maxwell A (2002) Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother 46:1805-1815
55. Pan XS, Fisher LM (1996) Cloning and characterisation of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol 178:4060-4069
56. Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon J, Blanche F (1994) Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 13:641-653
57. Yamagishi J, Kojima T, Oyamada Y, Fujimoto K, Hattori H, Nakamura S, Inoue M (1996) Alterations in DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 40:1157-1163
58. Tanaka M, Thang XY, Ishida H, Akasaka T, Sato K, Hayakawa I (1995) Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China. J Med Microbiol 42:214-219
59. Takahata M, Yonezawa M, Kurose S, Futakuchi N, Matsubara N, Watanabe Y, Narita H (1996) Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 38:543-546
60. Schmitz FJ, Hofmann B, Scheuring S, Kuckefahr M, Klootwijk M, Verhoef J, Fluit AC, Heinz HP, Kohrer K, Jones ME (1998) Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 41:481-484
61. Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D (1999) Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 26:281-287
62. Takahashi H, Kikuchi T, Shoji S, Fujimura S, Lutfor AB, Tokue Y, Nukiwa T, Watanabe A (1998) Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 41:49-57
63. Wang T, Tanaka M, Sato K (1998) Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother 42:236-240
64. Fournier B, Hooper DC (1998) Effects of mutations in grlA of topoisomerase VI from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob Agents Chemother 42:2109-2112
65. Fournier B, Hooper DC (1998) Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother 42:121-128
66. Tanaka M, Onodera Y, Uchida Y, Sato K, Hayakawa I (1997) Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 41:2362-2366
67. Blanche F, Cameron B, Bernard FX, Maton L, Manse B, Ferrero L, Ratet N, Leqoc C, Goniot A, Bisch D, Crouzet J (1996) Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother 40:2714-2720
68. Gootz TD, Zaniewski R, Haskell SL, Kaczmarek FS, Maurice AE (1999) Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother 43:1845-1855
69. Ruiz J, Sierra JM, De Anta MT, Vila J (2001) Characterisation of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro. Int J Antimicrob Agents 18:107-112
70. Takei M, Fukuda H, Kishii R, Hosaka M (2001) Target preference of 15 quinolones against Staphylococcus aureus based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 45:3544-3547
71. Ince D, Hooper DC (2000) Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother 44:3344-3350
72. Ince D, Hooper DC (2001) Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 45:2755-2764
73. Roychoudhury S, Twinem TL, Makin KM, McIntosh EJ, Ledoussal B, Catrenich CE (2001) Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae. J Antimicrob Chemother 48:29-36
74. Discotto LF, Lawrence LE, Denbleyker KL, Barett JF (2001) Staphylococcus aureus mutants selected by BMS-284756. Antimicrob Agents Chemother 45:3273-3275
75. Roychoudhury S, Twinem TL, Makin KM, Nienaber MA, Ledoussal B, Cartrenich CE (2001) Staphylococcus aureus mutants isolated via exposure to nonflourinated quinolones: detection of known and unique mutations. Antimicrob Agents Chemother 45:3422-3426
76. Shreedhan S, Peterson LR, Fisher LM (1991) Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 35:2151-2154
77. Dubin DT, Fitzgibbon JE, Nahvi MD, John JF (1999) Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin. Antimicrob Agents Chemother 43:1631-1637
78. Linde HJ, Schmidt M, Fuchs E, Reischl U, Niller HH, Lehn N (2001)In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother 45:1553-1557
79. Li Z, Deguchi T, Yasuda M, Kawamura T, Kanematsu E, Nishino Y, Ishihara S, Kawada Y (1998) Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother 42:3293-3295
80. Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tancovic J, Girard D, Courvalin P, Polzer RJ (1996) Activity of the new fluoroquinolone trovafloxacin against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae. Antimicrob Agents Chemother 40:2691-2697
81. Tankovic JB, Perichon B, Duval D, Courvalin P (1996) Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 40:2505-2510
82. Perichon BJ, Tankovic J, Courvalin P (1997) Characterisation of a mutation in the parE gene that causes fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 41:1166-1167
83. Pan XS, Fisher LM (1997) Targeting of DNA gyrase by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 41:471-474
84. Pan XS, Fisher LM (1998) DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother 42:2810-2816
85. Fukuda H, Hiramatsu K (1999) Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:410-412
86. Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum P (1999) In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:1177-1182
87. Varon E, Janoir C, Kitzis MD, Gutmann L (1999) ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:302-306
88. Taba H, Kusano N (1998) Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob Agents Chemother 42:2193-2196
89. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC (1999) Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC and parE loci. Antimicrob Agents Chemother 43:329-334
90. Pestova E, Beyer R, Cianciotto NP, Noskin GA, Peterson LR (1999) Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother 43:2000-2004
91. Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, Kohrer K, Schmitz FJ (2000) Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 44:462-466
92. Stewart BA, Johnson AP, Woodford N (2002) Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin. J Med Microbiol 48:1103-1106
93. Morris JE, Pan XS, Fisher LM (2002) Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity. Antimicrob Agents Chemother 46:582-585
94. Janoir C, Varon E, Kitzis MD, Gutmann L (2001) New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob Agents Chemother 45:952-955
95. Pan XS, Fisher LM (1999) Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. Antimicrob Agents Chemother 43:1129-1136
96. Fernandez-Moreira E, Balas D, Gonzalez I, de la Campa AG (2000) Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb Drug Resist 6:259-267
97. Pan XS, Yague G, Fisher LM (2001) Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels and phenotypes of wild-type and mutant proteins. Antimicrob Agents Chemother 45:3140-3147
98. Fisher LM, Yague G, Morris JE, Pan XS (2001) Cleavable complex formation with wild-type and mutant Streptococcus pneumoniae topoisomerase targets by gemifloxacin, an enhanced-affinity fluoroquinolone. J Antimicrob Chemother 47 [Suppl 2]:24
99. Nagai K, Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC (2001) Single- and multistep resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 48:365-374
100. Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM (2000) Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother 44:320-325
101. Fukuda H, Kishii R, Hosaka M (2001) Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae. Antimicrob Agents Chemother 45:1549-1553
102. Hartman-Neumann S, DenBleyker K, Pelose LA, Lawrence LE, Barett JF, Douherty TJ (2001) Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the Des-F(6) quinolone BMS-284756. Antimicrob Agents Chemother 45:2865-2870
103. Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L (1999)In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the par-parC region in Streptococcus mitis. J Infect Dis 180:555-558
104. Ferrandiz MJ, Fenoll A, Linares J, De la Campa AG (2000) Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 44:840-847
105. Bast DJ, de Azavedo JC, Tam TY, Kilburn L, Duncan C, Mandell LA, Davidson RJ, Low DE (2001) Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 45:2631-2634
106. Gonzalez I, Georgiou M, Alcaide F, Balas D, Linares J, DelaCampa AG (1998) Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 42:2792-2798
107. Kaneko A, Sasaki J, Shimadzu M, Kanamaya A, Saiki T, Kobayashi I (2000) Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. J Antimicrob Chemother 45:771-775
108. Guerin F, Varon E, Buu Hoi A, Gutmann L, Podglajen I (2000) Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans streptococci. Antimicrob Agents Chemother 44:2197-2200
109. Yan SS, Fox ML, Holland AM, Stock F, Gill VJ, Fedorko DP (2000) Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 44:3196-3198
110. Tankovic JF, Mahjoubi F, Courvalin P, Duval J, Leclero R (1996) Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 40:2558-2561
111. El Amin N, Jalal S, Wretlind B (1999) Alterations in GyrA and ParC associate with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother 43:947-949
112. Brisse S, Fluit AC, Wagner U, Heisig P, Milatovic D, Verhoef J, Scheuring S, Kohrer K, Schmitz FJ (1999) Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob Agents Chemother 43:2513-2516
113. Ubukata K, Itho NY, Konno M (1989) Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 33:1535-1539
114. Ohshita Y, Hiramatsu K, Yokota T (1990) A point mutation in norA gene is responsible for quinolone resistance in Staphylococcus aureus. Biochem Biophys Res Commun 172:1028-1034
115. Neyfakh AA (1992) The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob Agents Chemother 36:484-485
116. Kaatz GW, Seo SM (1995) Inducible NorA-mediated multi-drug resistance in Staphylococcus aureus. Antimicrob Agents Chemother 39:2650-2655
117. Kaatz GW, Seo SM, Ruble CA (1993) Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 37:1086-1094
118. Ng EY, Trucksis M, Hooper DC (1994) Quinolone resistance mediated by norA: physiological characterisation and relationship to flqB, a quinolone reistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother 38:1245-1255
119. Fournier B, Truong-Bolduc QC, Zhang XM, Hooper DC (2001) A mutation in the 5′untranslated region increases stability of norA mRNA, encoding a multidrug resistance transporter of Staphylococcus aureus. J Bacteriol 183:2367-2371
120. Yamada H, Kurose-Hamada S, Fukuda Y, Mitsuyama J, Takahata M, Minami S, Watanabe Y, Narita H (1997) Quinolone susceptibility of norA-disrupted Staphylococcus aureus. Antimicrob Agents Chemother 41:2308-2309
121. Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S (1996) Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 40:1835-1842
122. Schmitz FJ, Fluit AC, Luckefahr M, Engler B, Hofmann B, Verhoef J, Heinz HP, Hadding U, Jones ME (1998) The effect of reserpine, an inhibitor of multidrug efflux pump, on the in vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 42:807-810
123. Yu JL, Grinius L, Hooper DC (2002) NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol 184:1370-1377
124. Muñoz-Bellido JL,Alonzo Manzanares MA, Martínez Andrés JA, Gutiérrez-Zufiaurre MN, Oriz M, Segovia Hernández M, García-Rodríguez JA (1999) Efflux-pump-mediated quinolone resistance in Staphylococcus aureus strains wild-type gyrA, gyrB, grlA and norA. Antimicrob Agents Chemother 43:354-356
125. Sulavik CM, Barg NL (1998) Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance. Antimicrob Agents Chemother 42:3317-3319
126. Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ (1999) Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 43:335-340
127. Markham P, Westhaus E, Klyachko K, Johnson ME, Neyfakh AA (1999) Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob Agents Chemother 43:2404-2408
128. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR (2000) A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother 44:798-801
129. Neyfakh AA, Borsch CM, Kaatz GW (1993) Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 37:128-129
130. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ (1997) Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 41:1973-1978
131. Brenwald NP, Gell MJ, Wise R (1998) Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 42:2032-2035
132. Gill MJ, Brenwald NP, Wise R (1999) Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 43:187-189
133. Lynch C, Courvalin P, Nikaido H (1997) Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother 41:869-871
134. Boos M, Mayer S, Fischer A, Köhrer K, Scheuring S, Heisig P, Verhoef J, Fluit AC, Schmitz FJ (2001) In-vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob Agents Chemother 45:938-942
135. Cullis PM, Maxwell A, Weiner DP (1997) Exploiting nucleotide thiophosphates to probe mechanistic aspects of Escherichia coli DNA gyrase. Biochemistry 36:6059-6068
136. Kanematsu E, Deguchi T, Yasuda M, Kawamura T, Nishino Y, Kawada Y (1998) Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 42:433-435